What Researchers Did
A multi-centre North American consortium including Canadian researchers designed the framework for a clinical trial testing HBOT in patients hospitalized with moderate-to-severe ulcerative colitis (UC) flares.
What They Found
The team identified important gaps in how to design such trials, including the need for endoscopy to confirm eligibility (not just clinical scores alone), the need to track patient-reported symptoms like rectal bleeding and stool frequency, and the importance of standardizing steroid dosing and discharge criteria across sites to reduce confounding. They established a pragmatic trial framework using the PRECIS-2 tool to tailor enrollment to local patient populations.
What This Means for Canadian Patients
Patients hospitalized with severe UC flares face a high risk of needing surgery to remove their colon if standard steroid therapy fails. This trial framework is preparing the ground for a rigorous clinical study that could establish HBOT as a rescue option for this group, potentially helping some patients avoid colectomy. Canadians with treatment-resistant UC may benefit from future enrollment in studies like this.
Canadian Relevance
This study includes Canadian authors and is part of the NIDDK HBOT-UC Consortium, making it directly relevant to Canadian patients with inflammatory bowel disease.
Study Limitations
This paper describes trial design methodology rather than clinical outcomes, so no efficacy data on HBOT for UC flares are yet available from this group.